Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries
10+ emerging markets, Japan & ANZ transition in final phase
10+ emerging markets, Japan & ANZ transition in final phase
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
European operations' revenue grew 58.4% to Rs 599.7 crore
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Increased capability to produce medicines for challenging diseases including cancer
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Subscribe To Our Newsletter & Stay Updated